Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 4(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00131443Phase 2Completed

Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine

Role: lead

NCT00299234Phase 4Terminated

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

Role: lead

NCT00286988Phase 4Terminated

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

Role: lead

NCT00158002Phase 2Completed

A Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine

Role: lead

All 4 trials loaded